Vitamin-C verdict may spell trouble ahead for multinational Chinese companies
On 14 March, a federal jury in New York found Chinese vitamin-C manufacturer Hebei Welcome Pharmaceutical Co and its parent, North China Pharmaceutical Group Corp, liable for agreeing with other Chinese manufacturers to fix prices in the vitamin-C market.
The jury awarded $54.1m (£35m) in damages to the plaintiffs — purchasers including US food and drink companies, packagers, wholesalers and distributors — an amount that was then trebled by the presiding judge to an award of $162.3m in accordance with federal antitrust laws. Three other Chinese manufacturers involved in the conspiracy reached settlements with the plaintiffs prior to the announcement of the verdict…
If you are registered and logged in to the site, click on the link below to read the rest of the Allen & Overy briefing. If not, please register or sign in with your details below.
News from Allen & Overy
News from The Lawyer
Briefings from Allen & Overy
The ITC has reaffirmed its power to ban electronic transmissions from the US where those transmissions infringe an intellectual property right or are otherwise based on an unfair trade practice.
A new French law, the ‘Law to recapture the real economy’ (‘Loi visant à reconquérir l’économie réelle’ or ‘Loi Florange’), was made on 1 April 2014.
Analysis from The Lawyer
Imagine you’re the general counsel of London-based private equity investor BC Partners. You’re sipping on your coffee, hashing out the details of your imminent £382m investment into UK-based business publishing company Mergermarket.
‘Exotic’ investors and opportunities for legal work beyond M&A feature in The Lawyer’s high-level roundtable debate on south-east Europe